Market Closed -
Nasdaq
21:00:00 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
5.91
USD
|
+0.85%
|
|
+7.45%
|
-10.45%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,004
|
505.8
|
292.4
|
323.9
|
416.5
|
-
|
-
|
Enterprise Value (EV)
1 |
2,004
|
505.8
|
292.4
|
323.9
|
416.5
|
416.5
|
416.5
|
P/E ratio
|
-11.3
x
|
-5.86
x
|
-2.3
x
|
-2.75
x
|
-2.95
x
|
-2.65
x
|
-2.21
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
40.8
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
40.8
x
|
EV / EBITDA
|
-
|
-5.97
x
|
-2.51
x
|
-2.57
x
|
-3.39
x
|
-3.33
x
|
-3.08
x
|
EV / FCF
|
-39.3
x
|
-6.93
x
|
-2.81
x
|
-2.83
x
|
-4.16
x
|
-2.89
x
|
-2.2
x
|
FCF Yield
|
-2.55%
|
-14.4%
|
-35.6%
|
-35.3%
|
-24%
|
-34.6%
|
-45.4%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
32,595
|
32,949
|
48,814
|
49,072
|
70,468
|
-
|
-
|
Reference price
2 |
61.47
|
15.35
|
5.990
|
6.600
|
5.910
|
5.910
|
5.910
|
Announcement Date
|
25/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
10.2
|
EBITDA
1 |
-
|
-
|
-84.67
|
-116.3
|
-125.8
|
-123
|
-125
|
-135
|
EBIT
1 |
-
|
-51.51
|
-86.43
|
-119
|
-131.6
|
-132.9
|
-148.4
|
-180.3
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,767.5%
|
Earnings before Tax (EBT)
1 |
-
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-118.2
|
-136.5
|
-169
|
Net income
1 |
-21.08
|
-91.36
|
-86.08
|
-113.8
|
-117.5
|
-118.2
|
-140.4
|
-164
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,607.67%
|
EPS
2 |
-3.890
|
-5.440
|
-2.620
|
-2.610
|
-2.400
|
-2.002
|
-2.233
|
-2.670
|
Free Cash Flow
1 |
-
|
-51.02
|
-72.95
|
-104.1
|
-114.3
|
-100
|
-144
|
-189
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,852.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/06/20
|
25/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-25.49
|
-26.98
|
-29.6
|
-34.25
|
-33.52
|
-36.02
|
-27.31
|
-28.93
|
-30.51
|
-31
|
-31
|
-31
|
-31
|
-31
|
EBIT
1 |
-22.89
|
-26.1
|
-27.61
|
-30.26
|
-34.98
|
-34.31
|
-36.86
|
-29.29
|
-31.18
|
-32.76
|
-32.48
|
-32.77
|
-34.87
|
-31.96
|
-32.02
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-29.52
|
-28.54
|
-28.95
|
-31.24
|
-29.34
|
-29.39
|
Net income
1 |
-22.81
|
-25.99
|
-26.92
|
-28.34
|
-32.58
|
-30.82
|
-33.29
|
-25.64
|
-27.75
|
-29.52
|
-28.54
|
-28.95
|
-31.24
|
-29.34
|
-29.39
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.6900
|
-0.7900
|
-0.6100
|
-0.5800
|
-0.6700
|
-0.6300
|
-0.6800
|
-0.5200
|
-0.5700
|
-0.5800
|
-0.4717
|
-0.4800
|
-0.4883
|
-0.5267
|
-0.5300
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/22
|
12/05/22
|
11/08/22
|
09/11/22
|
16/03/23
|
11/05/23
|
10/08/23
|
09/11/23
|
21/03/24
|
09/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-51
|
-73
|
-104
|
-114
|
-100
|
-144
|
-189
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
7.51
|
5.03
|
47.1
|
28.1
|
1.09
|
3
|
4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
39.22%
|
Announcement Date
|
19/06/20
|
25/03/21
|
17/03/22
|
16/03/23
|
21/03/24
|
-
|
-
|
-
|
Last Close Price
5.91
USD Average target price
19.29
USD Spread / Average Target +226.32% Consensus |
1st Jan change
|
Capi.
|
---|
| -10.45% | 416M | | +15.20% | 121B | | +19.67% | 113B | | +18.95% | 26.02B | | -23.86% | 19.39B | | -19.03% | 15.91B | | -20.90% | 15.09B | | -46.14% | 15.06B | | +63.85% | 14.93B | | +4.49% | 13.85B |
Bio Therapeutic Drugs
|